OCRF-FUNDED RESEARCH PROJECT

LEVERAGING GENOMICS TO STOP DRUG RESISTANCE

Institution: QIMR Berghofer Research Medical Institute

Lead Researcher: Associate Professor Stacey Edwards

Funding Awarded: $494,958

Total Collaborative Funding: $300,000

Year/s: 2021-2024

Research Pillar: New & Effective Treatments

panel Image

Project Description:

Associate Professor Stacey Edwards is focused on finding new and more effective treatments for ovarian cancer that also manage recurrence of the disease. This project focuses on high-grade serous ovarian cancer, which is the most common and aggressive type of the disease. PARP inhibitors can be used to treat this type of ovarian cancer. They work by blocking the proteins that are repairing the DNA, leading to more DNA damage and cancer cell death. However, cancer cells often turn DNA repair pathways back on, which means that patients become resistant to this type of treatment, and it stops working. Associate Professor Edwards will investigate whether combining PARP inhibitors or chemotherapy with antisense oligonucleotides (an emerging area of drug development), would improve their effectiveness.

Expected/Achieved Outcomes:

Knowledge Building: If successful, this will be the first study to identify all molecules involved in drug resistance and assess the way that they function in tumours. These results will provide evidence that combined therapies could make initial treatment of patients more effective and reduce recurrence of ovarian cancer.

Project Status:

The project is currently underway.

Get the latest news, stories & updates.
The Ovarian Cancer Research Foundation acknowledges the Traditional Custodians of the lands upon which we work, strive, and learn, the Wurrundjiri Woi wurrung and Bunorung Boon wurrung peoples of the Kulin Nation. We pay our respects to Elders past and present, and extend this respect to all Aboriginal and Torres Strait Islander peoples in Australia and beyond.